EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte Studie

Effects of additional oral fosravuconazole l ‐lysine ethanolate therapy following inadequate response to initial treatment for onychomycosis: A multicenter, randomized controlled trial

Wataru Naka iD, Yuichiro Tsunemi iD

The Journal of Dermatology · 2024-07 · 51 (7) · 964-972

DOI: 10.1111/1346-8138.17193 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Dermatology, online erschienen am 14.03.2024. Verfasst von Wataru Naka und 1 weiteren Autor:innen. Beteiligte Einrichtung: Naka Dermatology Clinic, Saitama, Japan. Hauptthemen laut MEDLINE: Onychomycosis, Antifungal Agents, Triazoles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Sato Pharmaceutical Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Onychomycosis, a superficial fungal infection, develops when dermatophytes infect nail plate and beds. Fosravuconazole l ‐lysine ethanolate (F‐RVCZ), a fourth‐generation azole antifungal agent with potent antifungal activity and few drug interactions, was highly effective in a clinical trial, with a complete cure rate of 59.4% at 48 weeks after treatment initiation. However, some patients were not completely cured. To achieve a higher complete cure rate, additional therapy needs to be examined. We aimed to examine (i) the criteria for additional F‐RVCZ therapy in patients with an inadequate response to initial F‐RVCZ treatment for onychomycosis; (ii) the timing of additional therapy; and (iii) the effects of additional treatment. This was a multicenter, open‐label, three‐arm randomized clinical trial. Patients with onychomycosis were orally administered an approved dose of F‐RVCZ for 12 weeks, and its efficacy was assessed at week 24. Patients who demonstrated ≥55% reduction in nail involvement ratio at week 24 were included in Group X and followed up. Patients with

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OnychomycosisAntifungal AgentsTriazolesHumansFemaleMaleMiddle AgedAdultAdministration, OralTreatment OutcomeAgedFoot DermatosesThiazolesOrganophosphates

Stichwörter der Autor:innen

additional therapyfosravuconazolelong‐term observationonychomycosisrandomized controlled trial

Substanzen

Antifungal AgentsTriazolesER 30346ThiazolesOrganophosphates

Autor:innen und Institutionen

  • Naka Dermatology Clinic, Saitama, Japan.
  • Department of Dermatology, Saitama Medical University Hospital, Saitama, Japan.

ORCID-Profile: Wataru Naka, Yuichiro Tsunemi

Förderung

  • Sato Pharmaceutical Co., Ltd

Zitieren

APA

Naka, W., & Tsunemi, Y. (2024). Effects of additional oral fosravuconazole l ‐lysine ethanolate therapy following inadequate response to initial treatment for onychomycosis: A multicenter, randomized controlled trial. The Journal of Dermatology, 51(7), 964-972. https://doi.org/10.1111/1346-8138.17193

Vancouver

Naka W, Tsunemi Y. Effects of additional oral fosravuconazole l ‐lysine ethanolate therapy following inadequate response to initial treatment for onychomycosis: A multicenter, randomized controlled trial. The Journal of Dermatology. 2024;51(7):964-972. doi:10.1111/1346-8138.17193

BibTeX
@article{Naka2024,
  author = {Naka, Wataru and Tsunemi, Yuichiro},
  title = {Effects of additional oral fosravuconazole l ‐lysine ethanolate therapy following inadequate response to initial treatment for onychomycosis: A multicenter, randomized controlled trial},
  journal = {The Journal of Dermatology},
  year = {2024},
  volume = {51},
  number = {7},
  pages = {964--972},
  doi = {10.1111/1346-8138.17193}
}
Kostenlos starten →